This disclosure relates to modulators of liver receptor homologue 1 (LRH-1) and methods of managing disease and conditions related thereto. In certain embodiments, modulators are derivatives of hexahydropentalene. In certain embodiments, this disclosure relates to methods of treating or preventing cancer, diabetes, or cardiovascular disease by administering an effective amount of a hexahydropentalene derivative disclosed herein.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

Disclosed is a novel stabilizer represented by formula I,

##STR00001##

Further disclosed is a liquid crystal composition comprising a compound of formula I. The liquid crystal composition disclosed in the present invention has a low viscosity γ.sub.1, a moderate dielectric anisotropy Δ∈, a moderate optical anisotropy Δn, and most principally a high reliability, and can achieve a quick response of liquid crystal display.

Disclosed is a novel stabilizer represented by formula I,

##STR00001##

Further disclosed is a liquid crystal composition comprising a compound of formula I. The liquid crystal composition disclosed in the present invention has a low viscosity γ.sub.1, a moderate dielectric anisotropy Δ∈, a moderate optical anisotropy Δn, and most principally a high reliability, and can achieve a quick response of liquid crystal display.

The present disclosure provides certain indane compounds that are Hypoxia Inducible Factor 2α (HIF-2α) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of HIF-2α. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.